Genelux Corporation (NASDAQ:GNLX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $19.25.
GNLX has been the subject of a number of research reports. Wall Street Zen raised Genelux from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of Genelux in a report on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating on shares of Genelux in a report on Wednesday, July 23rd. Finally, Lake Street Capital started coverage on Genelux in a research note on Tuesday. They set a "buy" rating and a $16.00 price objective for the company.
Read Our Latest Stock Analysis on GNLX
Genelux Price Performance
Shares of NASDAQ:GNLX opened at $6.51 on Tuesday. The firm has a market capitalization of $245.90 million, a P/E ratio of -7.57 and a beta of -0.22. The business's 50-day moving average is $4.11 and its 200 day moving average is $3.30. Genelux has a 1 year low of $1.99 and a 1 year high of $6.52.
Genelux (NASDAQ:GNLX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. On average, analysts expect that Genelux will post -0.88 EPS for the current year.
Hedge Funds Weigh In On Genelux
Several institutional investors and hedge funds have recently modified their holdings of the business. Private Management Group Inc. purchased a new position in Genelux during the second quarter worth approximately $33,000. Advisor Resource Council acquired a new stake in Genelux in the 1st quarter valued at $34,000. Liberty Wealth Management LLC purchased a new stake in Genelux in the 1st quarter worth $45,000. 5T Wealth LLC acquired a new position in Genelux during the first quarter worth $49,000. Finally, American Century Companies Inc. purchased a new position in Genelux during the first quarter valued at $51,000. Hedge funds and other institutional investors own 37.33% of the company's stock.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.